BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21835787)

  • 1. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
    J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
    Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
    J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
    Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
    PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.
    Zhou T; Han Y; Dang Y; Wang X; Zheng YH
    Retrovirology; 2009 Apr; 6():31. PubMed ID: 19344514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
    Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
    Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
    Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
    J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.
    Albin JS; LaRue RS; Weaver JA; Brown WL; Shindo K; Harjes E; Matsuo H; Harris RS
    J Biol Chem; 2010 Dec; 285(52):40785-92. PubMed ID: 20971849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
    Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
    J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
    Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
    J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins.
    Virgen CA; Hatziioannou T
    J Virol; 2007 Dec; 81(24):13932-7. PubMed ID: 17942564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3F Constitutes a Barrier to Successful Cross-Species Transmission of Simian Immunodeficiency Virus SIVsmm to Humans.
    Nchioua R; Kmiec D; Gaba A; Stürzel CM; Follack T; Patrick S; Kirmaier A; Johnson WE; Hahn BH; Chelico L; Kirchhoff F
    J Virol; 2021 Aug; 95(17):e0080821. PubMed ID: 34132575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
    Dang Y; Wang X; Esselman WJ; Zheng YH
    J Virol; 2006 Nov; 80(21):10522-33. PubMed ID: 16920826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.